IONS
Overvalued by 180.2% based on the discounted cash flow analysis.
Market cap | $11.02 Billion |
---|---|
Enterprise Value | $9.66 Billion |
Dividend Yield | $- (-) |
Earnings per Share | $-3.04 |
Beta | 0.33 |
Outstanding Shares | 159,137,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -41.03 |
---|---|
PEG | 14.25 |
Price to Sales | 0.08 |
Price to Book Ratio | 23.05 |
Enterprise Value to Revenue | 0.07 |
Enterprise Value to EBIT | -0.07 |
Enterprise Value to Net Income | -37 |
Total Debt to Enterprise | 0.1 |
Debt to Equity | 1.47 |
No data
No data
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...